Be Clinical Raises ₹21 Cr Seed Extension Led by Sauce

The word “clinical” does unusual work on a skincare shelf. It asks a customer to trust the formula, the test behind it, the factory that made it, and the brand translating all of that into a claim small enough to fit on a box.

Be Clinical has raised ₹21 Cr, reported as about $2.2M, to put more operating weight behind that word. The New Delhi skin-longevity company closed a seed extension led by Sauce, with existing investor V3 Ventures and several angels participating. The financing will support R&D, clinical testing, manufacturing, hiring, portfolio expansion, and entry into new markets.

The round matters because Be Clinical is trying to own more of the evidence chain than a typical young consumer brand. The company says it develops formulations and manufactures products in-house, clinically tests products before launch, and registers trials with India's Clinical Trials Registry. As the catalog moves beyond facial skincare into body and haircare, the company must prove that its control system can expand as quickly as its product ambition.

What Happened

Be Clinical's ₹21 Cr seed extension was reported by Inc42 on August 22, 2026. Sauce led the round, while V3 Ventures returned as an investor. The angel participants named in the announcement were Mokobara co-founders Sangeet Agrawal and Navin Parwal, Reckitt executive Arjun Purkayastha, and Shaunak Chirayu Amin. The company did not disclose a valuation or ownership terms.

Public reporting identifies two earlier rounds: ₹2 Cr from Titan Capital and P-TAL founder Aditya Agrawal, followed by a ₹6 Cr seed round led by V3 Ventures with Titan Capital participating. Together with the extension, those announcements total ₹29 Cr. That figure is the sum of publicly reported rounds, not an audited statement of cash on the company's balance sheet.

From Botnal to Be Clinical

Founder Hemangi Dhir did not begin with the current brand. In her account of the company's history, she shut down Botnal after customer behavior kept pointing toward ageing concerns, then rebuilt the business as Be Clinical around skin longevity. The current brand launched in May 2025 after roughly two years of R&D.

That decision narrowed the promise while making execution more demanding. Be Clinical's official site currently lists targeted products such as PlumpX Serum, FirmX Serum, Revive 10 Eye Cream, Neck Repair Cream, SmoothX Hand Cream, and Blemish Balance Serum. The company positions those products around measurable concerns such as firmness, fine lines, the eye area, the neck, hands, and menopausal skin rather than a high-volume stream of trend-led launches.

What the Capital Is Buying

Be Clinical plans to use the extension across the parts of the company that sit behind product claims. The announced priorities include deeper R&D and clinical testing, more manufacturing capacity, expansion across skin, body, and haircare, team growth, and entry into new markets and geographies. This is a broader mandate than customer acquisition or inventory alone.

The company says formulation and manufacturing are handled in-house. On its website, Be Clinical also says products are dermatologically tested and that clinical trials are registered with India's Clinical Trials Registry. Individual registry identifiers were not located during DevCuration's research, so those statements remain company-reported and no specific efficacy result is presented here as independently validated.

Traction With an Evidence Label

At the time of the announcement, Be Clinical said it had delivered 1.2 lakh orders since launch and was seeing healthy repeat purchases. A later founder post cited 1.5 lakh orders and a 25% repeat-purchase rate, while V3 Ventures said sales had grown 5x in nine months and the business remained profitable. Those figures help explain investor interest, but they are company and investor statements rather than audited results.

The order count is still useful when read with the company's operating choices. A repeat purchase in skincare does not validate every clinical claim, but it does show whether a product can survive beyond the first impression, influencer post, or acquisition offer. Be Clinical's next phase adds a harder test: whether repeat behavior and product trust remain intact as manufacturing volume and category breadth increase.

Why Investors Are Following the Evidence Stack

Sauce described Be Clinical as a full-stack business with in-house R&D, manufacturing, and clinically tested formulations. V3 Ventures pointed to sales growth, reported profitability, the anti-ageing wedge, and in-house manufacturing as reasons for returning. Both arguments treat the operational model as part of the brand rather than an invisible supplier decision.

That distinction matters in beauty and personal care because the word “clinical” can become cheap before the work behind it does. A brand can buy distribution, outsource production, and build an efficient acquisition funnel. Maintaining control across formulation changes, batch production, testing, packaging, customer education, and product expansion requires a different kind of capital and management attention.

What This Signals for Consumer Brands

Be Clinical is expanding at the point where a focused thesis can become either a platform or a blur. Moving into body and haircare can increase customer value and make the longevity position larger, but every new formula and batch increases the amount of proof the company must manage. The same operating model that helped distinguish a compact catalog now has to work under more complexity.

For founders and investors, the signal is not that every beauty company should own a factory. It is that a performance-led brand must know which layer of proof it cannot afford to rent blindly. Be Clinical has chosen formulation, testing, and manufacturing as those layers, and the ₹21 Cr extension buys the company time and capacity to carry that choice into a wider catalog. Each new product will put the word “clinical” back on trial with the customers deciding whether to order again.